DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

(2020)   Nature Microbiology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports

(2020) André J. Scheen et al.   DIABETES & METABOLISM

COVID-19 and diabetes: Can DPP4 inhibition play a role?

(2020) Gianluca Iacobellis   DIABETES RESEARCH AND CLINICAL PRACTICE

COVID-19 and diabetes: Knowledge in progress

(2020) Akhtar Hussain et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Coronavirus Infections and Type 2 Diabetes—Shared Pathways with Therapeutic Implications

(2020) Daniel J Drucker   ENDOCRINE REVIEWS

Is SARS-CoV-2 Also an Enteric Pathogen With Potential Fecal–Oral Transmission? A COVID-19 Virological and Clinical Review

(2020) Siyuan Ding et al.   GASTROENTEROLOGY

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

(2020) Jing Yang et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Do novel drugs for diabetes help in COVID ‐19? Another brick in the wall?

(2020) Alicja Krejner‐Bienias et al.   Journal of Diabetes

COVID‐19 and comorbidities: A role for dipeptidyl peptidase 4 ( DPP4 ) in disease severity?

(2020) Margaret F. Bassendine et al.   Journal of Diabetes

Molecular immune pathogenesis and diagnosis of COVID-19

(2020) Xiaowei Li et al.   Journal of Pharmaceutical Analysis

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

(2020) Sebastiano Bruno Solerte et al.   ACTA DIABETOLOGICA

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

(2020) Julia Hippisley-Cox et al.   HEART

Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis

(2020) Qianwen Zhao et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome

(2020) Loris Roncon et al.   JOURNAL OF CLINICAL VIROLOGY

Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19

(2020) Fang Liu et al.   JOURNAL OF CLINICAL VIROLOGY

A cheap steroid is the first drug shown to reduce death in COVID-19 patients

(2020) Kai Kupferschmidt   SCIENCE

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike

(2020) Yu Li et al.   iScience

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

(2020) Sebastiano Bruno Solerte et al.   DIABETES CARE

Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections

(2020) Kristina Schlicht et al.   INTERNATIONAL JOURNAL OF OBESITY

A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2

(2020) Cecy R Xi et al.   MOLECULES

Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus

(2019) Giorgio Sesti et al.   ACTA DIABETOLOGICA

Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice

(2019) Yuta Takagaki et al.   Scientific Reports

Clinical Use of DPP-4 Inhibitors

(2019) Baptist Gallwitz   Frontiers in Endocrinology

Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus

(2018) Kyung-Soo Inn et al.   VIROLOGY

Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4

(2018) A. Casrouge et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease

(2018) Abdullah Algaissi et al.   JOURNAL OF INFECTIOUS DISEASES

A Randomized, Double-Blinded, Placebo-Controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed HIV Infection

(2018) Michael P Dubé et al.   CLINICAL INFECTIOUS DISEASES

Identification of senescent cell surface targetable protein DPP4

(2017) Kyoung Mi Kim et al.   GENES & DEVELOPMENT

Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system

(2016) C. Klemann et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The effect of dipeptidyl peptidase-IV inhibition on circulating T cell subpopulations in patients with type 2 diabetes mellitus

(2016) Lucie Sromova et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs – An Ab Initio Fragment Molecular Orbital Study

(2016) Sundaram Arulmozhiraja et al.   PLoS One

DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials

(2015) Wenjia Yang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study

(2015) Rogier Wvan der Zanden et al.   PLoS One

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease

(2015) Usha Panchapakesan et al.   Frontiers in Immunology

DPP4 in diabetes

(2015) Diana Röhrborn   Frontiers in Immunology

Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study

(2013) J. D. Price et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats

(2013) Kosuke Kaji et al.   JOURNAL OF GASTROENTEROLOGY

Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus

(2013) V. S. Raj et al.   JOURNAL OF VIROLOGY

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

(2013) V. Stalin Raj et al.   NATURE

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

(2012) K. Gooßen et al.   DIABETES OBESITY & METABOLISM

Sitagliptin Exerts an Antinflammatory Action

(2012) Antoine Makdissi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome

(2011) D. Lamers et al.   DIABETES

Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV

(2010) Armanda Casrouge et al.   JOURNAL OF CLINICAL INVESTIGATION

Soluble CD26 / Dipeptidyl Peptidase IV Enhances Human Lymphocyte Proliferation In Vitro Independent of Dipeptidyl Peptidase Enzyme Activity and Adenosine Deaminase Binding

(2010) D. M. T. Yu et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses

(2009) Kalpit A Vora et al.   BMC IMMUNOLOGY